SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026.
Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.32 per share a year ago.
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2 nd half of 2026
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR repertoire
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced Therapy (RMAT) designation and CDRP participation provide opportunity for expedited regulatory pathway and advancement of FT819 Phase 2 potentially registrational clinical trial in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has selected FT819 for participation in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program for treatment of moderate to severe systemic lupus erythematosus (SLE). The FDA CDRP Program is a highly selective initiative, with no more than nine proposals accepted annually across the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER).
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836, will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston, MA, May 11–15, 2026. Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance therapy without the use of conditioning chemotherapy to drive B cell depletion and improve patient outcome.
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2026, the Company granted restricted stock units (RSUs) representing 30,200 shares of its common stock to one newly-hired non-executive employee.
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2026, the Company granted restricted stock units (RSUs) representing 30,200 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be featured at the Congress of Clinical Rheumatology – East meeting, being held in Destin, FL on April 30 - May 3, 2026. The Company is participating in a Poster Rounding Session and will present an encore of its clinical data from the systemic lupus erythematosus (SLE) study arm of its ongoing Phase 1 trial evaluating FT819 in various autoimmune diseases.
Fate Therapeutics (NASDAQ: FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing "off-the-shelf" CAR T-cell therapies, highlighting clinical progress in autoimmune disease with FT819 and early proof-of-concept signals in solid tumors with FT836. President and CEO Bob Valamehr was joined by Chief Financial Officer Kamal Adawi. Positioning CAR T as
